Featured

BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.

BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.

David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.

BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.

We’re proud to be recognised on this prestigious list for our work in AI-driven chemical design. Our compound design is based upon complex multiparametric optimisations which aim to cut the time and cost of designing a drug.